Document is current

Article History

Received: 26 March 2019

Accepted: 21 May 2019

First Online: 15 June 2019

Compliance with ethical standards

:

: This work was supported by GlaxoSmithKline plc (GSK) through a contract with Medica Scientia Innovation Research (MedSIR), an academic research organization focused on independent clinical research development. Joaquín Gavilá: Roche, Novartis, Celgene (H, SAB); César Augusto Rodríguez Sánchez: Roche, Novartis, Celgene, Eisai, AstraZeneca (H, SAB); Javier Cortés: Roche, Celgene (C/A, H), Eisai, Novartis (H); Antonio Llombart-Cussac: Roche, GlaxoSmithKline, Novartis, Celgene, Eisai, AstraZeneca (H, SAB), GlaxoSmithKline, Sanofi, Puma Biotechnology (RF); all remaining authors have declared no financial relationships. (C/A) Consulting/advisory relationship; (RF) research funding; (E) employment; (ET) expert testimony; (H) honoraria received; (OI) ownership interests; (IP) intellectual property rights/inventor/patent holder; (SAB) scientific advisory board.

: The protocol of this trial and informed consent were approved by the ethics committee of each participating hospital and the study has been performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. This study was classified by the Spanish Agency of Medicines and Health Products.

: Written informed consent was obtained from all individual participants included in the study.